CASE REPORT

Transiently elevated plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine: Unreported laboratory findings in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation

Caitlin A. Chang1 | Xing-Chang Wei2 | Steven R. Martin3,4 | David S. Sinasac1,4 | Walla Al-Hertani1,3,4,5

1Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
2Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
3Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
4Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada
5Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts

Correspondence
Walla Al-Hertani, Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115.
Email: walla.al-hertani@childrens.harvard.edu

Communicating Editor: Viktor Kožich

Abstract

We report on a 5-year-old female born to consanguineous parents, ascertained at the age of 23 months for an elevated plasma methionine level, a mildly abnormal total plasma homocysteine (tHcy), and elevated aminotransferases. She had global developmental delay, microcephaly, dysmorphic facial features, hypotonia, nystagmus and tremor in her upper extremities. Metabolic investigations demonstrated elevations in plasma methionine, plasma S-adenosylmethionine (SAM) and plasma S-adenosylhomocysteine (SAH), with normal urine adenosine levels. Some of the elevations persisted for over 1 year. Sequencing of the ADK and AHCY genes was negative for causative variants. Plasma methionine normalized 1 year after ascertainment, but SAM and SAH continued to be elevated for six more months before normalization, and aminotransferases remained mildly elevated. Whole exome sequencing demonstrated a homozygous pathogenic variant; NM_018297.3(NGLY1):c.1405C>T (p.Arg469*) in exon 9 of the NGLY1 gene, for which both parents were heterozygous. To our knowledge, this is the first report of NGLY1 deficiency with elevations in plasma methionine, SAM and SAH and a slight elevation of tHcy. Less than 20 patients have been reported with NGLY1 deficiency worldwide and this case expands on the biochemical phenotype of this newly discovered inborn error of metabolism.

KEYWORDS
disorders of deglycosylation, methionine, NGLY1, SAH, SAM

1 | INTRODUCTION

N-glycanase 1 (NGLY1) deficiency was first reported in 2012,1 and is the first described congenital disorder of deglycosylation (NGLY1-CDDG).2 It is inherited in an autosomal recessive manner, and results in multi-system involvement with dysmorphic features, acquired microcephaly, severe hypotonia, seizures, poor growth, global developmental delay, movement disorder, and alacrima/hypolacrimal. Herein we describe a patient found to be homozygous for a pathogenic variant NM_018297.3(NGLY1):c.1405C>T (p.Arg469*) in the NGLY1 gene. Her features included global
developmental delay, microcephaly, dysmorphic facial features, hypotonia, hypolacrimation, and tremor in the upper extremities. Novel findings included initially persistent, but resolving elevations in plasma methionine, plasma S-adenosylmethionine (SAM) and plasma S-adenosylhomocysteine (SAH), but with normal urine adenosine levels. To our knowledge, fewer than 20 patients have been reported with NGLY1 deficiency worldwide. Our patient highlights an unreported presentation of NGLY1 deficiency and suggests possible additional pathways for investigation.

2 | PATIENT REPORT

The patient was born to a healthy 30-year-old Gravida 3 Para 2 mother at 32+2 weeks gestation, via Caesarian section, for decreased fetal heart rate. Birthweight was 1255 g (10th percentile), length was 38 cm (10th percentile), and head circumference was 28.5 cm (45th percentile). Her parents are of Libyan descent and first cousins. Both parents were healthy, as were the proband's two older male siblings. The patient required an 8-week stay in the NICU for management of feeding and growth difficulties. Aminotransferases in the newborn period were normal.

Elevated aminotransferases were first noted at 23 months of age as part of a workup for failure to thrive; AST of 358 U/L (normal: 10-45 U/L) and ALT of 853 U/L (normal: 1-35 U/L) and GGT of 101 U/L (normal: 8-35 U/L). Alpha Fetoprotein was within normal limits for her age. An initial search for alpha-1 antitrypsin deficiency, cystic fibrosis, infectious and autoimmune etiologies was negative, and a liver ultrasound for structural changes was normal. Liver biopsy was not performed. At 3 years, the GGT normalized but aminotransferases remained elevated, with AST 216 U/L at 3 years and 58 U/L at 5 years of age, and ALT 453 U/L at 3 years and 57 U/L at 5 years of age.

A brain MRI at 2 years of age demonstrated age-appropriate myelination with mildly prominent cerebral sulci, lateral and third ventricles, consistent with cerebral atrophy (Figure 1A). There were no documented seizures. She had a longstanding history of tremor in the upper extremities bilaterally, as well as weakness in her legs. She was followed by ophthalmology for myopic astigmatism, esotropia, and hypolacrimation, with normal dilated fundus examination. Hearing was normal. At 5 years of age, brain MRI demonstrated persistent mildly prominent cerebral sulci, lateral, and third ventricles (Figure 1B). 1H-magnetic resonance spectroscopy was normal.

An echocardiogram performed at 1 month of age demonstrated small atrial septal defect, patent ductus arteriosus, and mild right and left ventricular hypertrophy, with normalization on repeat. Electrocardiogram was normal. Complete blood counts and coagulation studies, albumin, immunoglobins, and thyroid studies were normal. There was no history of lactic acidosis. She had two fractures of the left lower extremity, after trauma. A bone age performed at 4 years; 4 months was within normal limits. Bone mineral density was reported as low, with a lumbar Z score of −2.1 (0.379 g/cm²). She was small for age, with measurements consistently at or just above the third percentile for height, weight, and head circumference.

At 5 years of age, development was delayed globally. She was unable to walk unassisted until 4 years of age. She was able to walk up and down stairs with assistance. She had between 15 and 20 words. She was able to follow two-step commands, and primarily communicated by taking one of her parents' hands or pointing. Fine motor development was delayed, but she was able to finger feed and hold a cup and a pencil with a fisted grasp. Social development was

---

**FIGURE 1** Brain MRI. T2-weighted images at age of 24 months (A) and 5 years (B) show lateral ventricles and cerebral sulci that are mildly prominent for age.
notable for social anxiety, but she demonstrated good eye contact and a social smile. She was not yet toilet trained.

On examination at 5 years of age, her weight was 18.9 kg (50th percentile), height 107 cm (25th percentile), and head circumference 48 cm (3rd percentile), consistent with microcephaly. She had dysmorphic facial features including deep-set eyes with long eyelashes, short palpebral fissures, and synophrys with full, arched eyebrows. Extremities were remarkable for bilateral 5th finger clinodactyly and fetal pads on all fingers. Cardiac, respiratory, and abdominal examination was unremarkable. There was no scoliosis. On neurological exam, she had increased tone with slight catching in the upper extremities bilaterally, and peripheral tremor in her upper extremities. Tone in the lower extremities was normal. She had decreased deep tendon reflexes throughout both upper and lower extremities. She was able to walk independently with a forward-leaning and wide-based gait but was unable to run.

3 | MATERIALS AND METHODS

3.1 | Cytogenetic investigations

Comparative genomic hybridization (CGH) oligoarray using the platform (CytoChipTM ISCA 8x60K v2.0) was performed on DNA extracted from peripheral whole blood.

3.2 | Biochemical testing

Plasma amino acids were quantitated after post-column ninhydrin derivatization using a Biochrom 30+ amino acid analyzer (Biochrom Ltd, Cambridge, UK). Total homocysteine was measured using a heavy-isotope dilution method following dithiothreitol reduction of disulfide bonds by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) as previously described.\(^3\) Plasma SAM and SAH were measured using a heavy-isotope dilution method after initial sample acidification, followed by neutralization and solid phase extraction by LC-MS/MS as previously described.\(^4\) Urine creatine/guanidinoacetate was measured at the Biochemical Genetics Laboratory at the Hospital for Sick Children (Toronto, Ontario, Canada), and urine purines and pyrimidines at the Laboratoire de génétique biochimique at the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Sherbrooke, Québec, Canada).

3.3 | Genetic analysis

Gene sequencing of the *AHCY* gene was performed at Baylor Miraca Genetics Laboratory (Houston, Texas). Gene sequencing of the *ADK* gene was performed at Centogene/Life Labs Laboratory (Rostock, Germany). XomeDxSlice analysis of the *ADA, GNMT, MAT1A, MTHFR*, and *SLC6A8* genes was performed at GeneDx Laboratory (Gaithersburg, Maryland).

Whole exome sequencing (WES) trio after slice was performed at GeneDx Laboratory (Gaithersburg, Maryland). Using genomic DNA extracted from peripheral lymphocytes, the Agilent Clinical Research Exome kit was used to target the exonic regions and flanking splice junctions of the genome. The targeted regions were sequenced simultaneously by massively parallel (NextGen) sequencing on an Illumina HiSeq sequencing system with 100 bp paired-end reads. Bi-directional sequence was assembled, aligned to reference gene sequences based on human genome build GRCh37/UCSC hg19, and analyzed for sequencing variants using a custom-developed analysis tool (Xome Analyzer). The mean depth of coverage was 180× and quality threshold was 97.9%. Sanger sequencing was performed in the laboratory on the proband’s and parents’ DNA for variant confirmation.

4 | RESULTS

4.1 | Cytogenetic investigations

The array CGH was reported as normal female.

4.2 | Biochemical testing

Plasma amino acid analysis at 23 months of age demonstrated an isolated 4.7-fold elevation in plasma methionine at 212 μmol/L (Normal: 10-45 μmol/L), and marginally elevated plasma total homocysteine level of 14.7 μmol/L (Normal: 3.1-11.1 μmol/L). Plasma SAM had a 3.8-fold elevation at 505 nmol/L (Normal: 86-132 nmol/L), and plasma SAH had a 6.4-fold elevation at 186 nmol/L (Normal: 9-29 nmol/L). In addition, urine creatine was elevated at 1500 mmol/mol creatinine (normal: 14-830 mmol/mol creatinine) and urine guanidinoacetate was normal at 124 mmol/mol creatinine (normal: 5-150 mmol/mol creatinine). She had normal urine adenosine levels. Creatine kinase (CK) was normal at 97 IU/L.

Plasma amino acids were repeated at 2 years, 2 months of age and she continued to have a 1.8-fold elevation in plasma methionine (but within the context of other elevated amino acids suggestive of a nonfasted specimen), but with a normal plasma total homocysteine at 6.3 μmol/L. There remained a 2.3-fold elevation of SAM, and an 8.1-fold elevation in SAH. At 3 years of age, there was normalization of the plasma amino acids but persistence of elevated SAM (1.6-fold) and SAH (2.4-fold). At 4 years, 7 months of age, SAM was still marginally elevated, and SAH normalized. SAM-to-SAH ratios ranged from 1.31 to 3 between 23 months and 3 years of age and normalized by 4.7 years of age. Urine creatine and guanidinoacetate levels normalized by 5 years of age as well.
4.2.1 Molecular genetic testing

No pathogenic variants were found in the ADK, ACHY, ADA, GNMT, MAT1A, MTHFR, and SLC6A8 genes. WES trio performed on the proband and both parents demonstrated a homozygous NM_018297.3(NGLY1):c.1405C>T (p.Arg469*) pathogenic variant in NGLY1 in the proband, and heterozygosity for this NGLY1 variant in the patient's mother and father. The variant had been reported in the homozygous state in an individual with unclassified epilepsy and was rare, with an allele frequency of $1.65 \times 10^{-5}$ in ExAC, and no homozygotes reported. At the time of the writing of this manuscript, the variant was reported in ClinVar 3 times as pathogenic (one submission representing our patient). It is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated RNA decay.

5 DISCUSSION

NGLY1-CDDG presents with abnormal tear production, choreoathetosis, liver dysfunction, developmental delay, hypotonia, peripheral neuropathy, EEG abnormalities, and microcephaly (Table 1). Previously reported hepatic findings include elevated aminotransferases, fibrosis, neonatal jaundice, and intrahepatic cytoplasmic inclusions on biopsy. A publication from 2017 which prospectively phenotyped patients with NGLY1-CDDG documented transient elevation of aminotransferases during the first 2 years of life, with normalization on average at age 4. Half of this cohort of 12 patients had normal abdominal ultrasound results, with abnormalities in the remainder including splenomegaly, steatosis, hepatomegaly, and coarse or inhomogeneous liver echotexture, and 3 of the 12 individuals had elevated fibroscan scores demonstrating possible liver fibrosis.

The mechanism by which loss of NGLY1 activity leads to the clinical phenotype is not well understood. Loss-of-function mutations in NGLY1 appears to lead to accumulation of misfolded proteins, which may interfere with cellular functions. The enzyme is known to play a key role in quality control of misfolded N-glycosylated proteins, as cleavage of the attached N-glycans directly precedes proteasomal degradation. Regulation of proteolysis through de-N-glycosylation of Nrf1, a transcription factor that upregulates proteasome subunit gene expression, has also been demonstrated in vitro, with a clear role between NGLY1 activity and regulation of proteostasis. In the absence of NGLY1, cytosolic endo-β-N-acetylglucosaminidase (ENGase) acts on misfolded glycoproteins to generate N-GlcNAc proteins, which are hypothesized to cause toxic effects on cells through protein aggregation and/or impairment of intracellular signalling pathways. Patients who have NGLY1 deficiency have been described to have mitochondrial dysfunction as observed on muscle and liver biopsy and in vitro, potentially implicating a role for NGLY1 in the respiratory chain.

Our patient demonstrated elevations in methionine, SAM, and SAH, and mild elevation in homocysteine. To our knowledge, this is the first report of this biochemical profile in patients with NGLY1-CDDG. Methionine is activated in an ATP-dependent reaction to form SAM, which plays a major role in methyl donation during biosynthetic reactions. SAH is formed from the demethylation of SAM following donation of the methyl group to an acceptor; the adenosyl group is subsequently removed to form homocysteine (Figure 2).

With respect to the potential mechanism that may underlie the SAM and SAH elevations in our patient, we considered several possibilities. Elevations in homocysteine levels due to low dietary folate or B12 may present with low SAM:SAH ratios and elevated SAH, but typically not with elevated SAM. Folate was not checked, but vitamin B12 and methylmalonic levels were normal, suggesting that this is a less likely explanation for our patient. While liver disease in patients with NGLY1-CDDG has been characterized in multiple reports, hepatic SAM metabolism in patients with chronic liver disease typically shows patterns of low SAM due to SAM depletion and/or reduced synthesis, rather than elevation. Therefore, this is an unlikely explanation as well. Very elevated methionine levels (up to 26-fold) and elevated SAM have been described in patients with hepatic mitochondrial DNA (mtDNA) depletion syndromes, but were not accompanied by elevations in SAH. It is also possible that muscle involvement may be contributing to our patient's presentation, however, her creatine kinase level has been normal to date.

Genetic testing in our patient for enzymes involved in methylation was unrevealing. Multiple levels of control over methylation enzymes have been described, including oxidative stress, metabolites from the same or related pathways, and hormones and nutrients. We suggest that dysregulation of one or more enzymes involved in methylation may be the cause for our patient's presentation, through one or more of the pathways impacted by loss of NGLY1. The elevations in methionine, homocysteine, SAM, and SAH improved over time, suggesting that the implicated enzymatic dysregulation is reversible. She also had low SAM:SAH ratios from 23 months to 3 years of age, which may suggest reduced methylation capacity. While our findings are limited to a single case, it may be informative to explore whether SAM and SAH are also dysregulated in other patients with NGLY1-CDDG, and whether a pattern of methylation differences can be detected in this group of patients.
| Patients | Gender | Pregnancy Complications | Development | Intellectual disability | Neurological | Movement | Brain MRI abnormalities | Microcephaly | Eye | Hypotonia | Dermatological | Other | Orthopedic | Ophthalmological | Other |
|----------|--------|-------------------------|-------------|------------------------|-------------|---------|----------------------|-------------|-----|-----------|----------------|-------|------------|----------------|-------|
| Patient 1 | M      | Birth weight (g)         | 2722        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 2 | M      | Birth weight (g)         | 2603        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 3 | M      | Birth weight (g)         | 2500        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 4 | M      | Birth weight (g)         | 2400        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 5 | M      | Birth weight (g)         | 2300        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 6 | M      | Birth weight (g)         | 2200        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 7 | M      | Birth weight (g)         | 2100        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 8 | M      | Birth weight (g)         | 2000        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 9 | M      | Birth weight (g)         | 1900        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 10| M      | Birth weight (g)         | 1800        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 11| M      | Birth weight (g)         | 1700        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 12| M      | Birth weight (g)         | 1600        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 13| M      | Birth weight (g)         | 1500        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 14| M      | Birth weight (g)         | 1400        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 15| M      | Birth weight (g)         | 1300        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 16| M      | Birth weight (g)         | 1200        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 17| M      | Birth weight (g)         | 1100        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 18| M      | Birth weight (g)         | 1000        | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 19| M      | Birth weight (g)         | 900         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 20| M      | Birth weight (g)         | 800         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 21| M      | Birth weight (g)         | 700         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 22| M      | Birth weight (g)         | 600         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 23| M      | Birth weight (g)         | 500         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 24| M      | Birth weight (g)         | 400         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 25| M      | Birth weight (g)         | 300         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 26| M      | Birth weight (g)         | 200         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |
| Patient 27| M      | Birth weight (g)         | 100         | 1285                   | +           | +       | +                   | +           | +  | +         | +               | +     | +          | +              | +     |

(Continues)
### TABLE 1 (Continued)

| Patients | Patient reference | One patient | Trio 2 | Patient 1 | Patient 2 | Patient 3 | Patient 4 (n=6) | Patient 5 | Patient 6 (n=1) | Patient 7 | Patient 8 (n=1) | Patient 1 | Patient 2 | Patients (n=12) |
|----------|-------------------|-------------|--------|-----------|-----------|-----------|----------------|-----------|----------------|-----------|----------------|-----------|-----------|-----------------|
| **Biochemicals** | | | | | | | | | | | | | | |
| **Hypohyaline** | | | | | | | | | | | | | | |
| **Audiological** | | | | | | | | | | | | | | |
| **Cranial** | | | | | | | | | | | | | | |
| **Sleep** | | | | | | | | | | | | | | |
| **Gastrointestinal** | | | | | | | | | | | | | | |
| **Musculoskeletal** | | | | | | | | | | | | | | |
| **Neurological** | | | | | | | | | | | | | | |
| **Hematological** | | | | | | | | | | | | | | |
| **Immunologic** | | | | | | | | | | | | | | |
| **Other** | | | | | | | | | | | | | | |

(Continues)
TABLE 1 (Continued)

| Patients | Patient reference | One patient | Type 1 | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 (Sib of 7) | Patient 7 | Patient 8 (Sib of 8) | Patient 9 | Patient 10 | Patient 11 | Patient 12 (n = 12) |
|----------|-------------------|-------------|--------|-----------|-----------|-----------|-----------|-----------|---------------------|-----------|---------------------|-----------|-------------|-------------|---------------------|
| Lab and biochemical findings | | | | | | | | | | | | | | | | |
| Muscle biopsy | | | | | | | | | | | | | | | | |
| More variation in muscle, normal mitochondrial stain | | | | | | | | | | | | | | | | |
| TIEF | normal | normal | | | | | | | | | | | | | | |
| O-Glycan analysis | normal | | | | | | | | | | | | | | | |
| Lactic acidosis | | | | | | | | | | | | | | | | |
| Urine MPS | | | | | | | | | | | | | | | | |
| Other | | | | | | | | | | | | | | | | |
| Dysmorphic features | | | | | | | | | | | | | | | | |
| Deep-set eyes, small palpebral fissures, synophrys, full, arched eyebrows, bilateral 5th finger clinodactyly, fetal pads on all fingers | | | | | | | | | | | | | | | | |
| Small hands/feet | | | | | | | | | | | | | | | | |
| Deceased age 5 years, viral illness/prolonged seizure | | | | | | | | | | | | | | | | |
| Other remarks | | | | | | | | | | | | | | | | |
| Patent ductus arteriosus and atrial septal defect, resolved | | | | | | | | | | | | | | | | |
| AFP 1.63 MoM, uE3 0.26 MoM, hCG 0.54 MoM, inhibin 1.02 MoM | | | | | | | | | | | | | | | | |
| AFP 1.97 MoM, uE3 0.24 MoM, hCG 0.48 MoM | | | | | | | | | | | | | | | | |
| Six individuals (patients 2, 3, 4, 9, 11, and 12) were included in previous clinical publications | | | | | | | | | | | | | | | | |

Abbreviations: AFP, alpha feto-protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C/S, Caeserian section; CSF, cerebrospinal fluid; DTRs, deep tendon reflexes; EEG, electroencephalogram; ER, endoplasmic reticulum; F, female; FHR, fetal heart rate; GERD, gastroesophageal reflux; hCG, human chorionic gonadotropin; IUGR, intrauterine growth restriction; LFT, liver function test; M, male; MMR = measles/mumps/rubella; MoM, multiples of the median; MPS, mucopolysaccharides; MRI, magnetic resonance imaging; QTcB, QT interval corrected for heart rate; Sib, sibling; TG, triglycerides; TIEF, transferrin isoelectric focusing; uE3, unconjugated estradiol.
6 | CONCLUSION

In summary, we report a new case of NGLY1-CDDG with transient elevations in methionine and homocysteine, as well as SAM and SAH, which are involved in single-carbon metabolism. Our goal is to expand the reported biochemical phenotype of patients with NGLY1-CDDG, with possible future research avenues including evaluation of the regulation of enzymes involved in methylation through one or more of the pathways impacted by loss of NGLY1.

AUTHOR CONTRIBUTIONS

C. A. C.—Contributed significantly to writing the manuscript, saw the patient, and consented the family for publication. S. R. M.—Gastroenterologist following the patient, critically reviewed and edited the manuscript. D. S. S.—Biochemical Geneticist essential in the completion, analysis, and interpretation of biochemical laboratory results, critically reviewed and edited the manuscript. W. A.-H.—Primary provider for the patient and directed diagnostic laboratory investigations, confirmation of diagnosis, follow-up and management of the patient. Responsible for planning, conducting, and reporting the case. Contributed significantly to the manuscript, and critically reviewed and edited the manuscript.

PATIENT CONSENT

The patient was seen at the Alberta Children's Hospital in Calgary, Alberta, Canada, and written parental consent was obtained for publication.

ORCID

Walla Al-Hertani https://orcid.org/0000-0001-8967-8640

REFERENCES

1. Need AC, Shashi V, Hitomi Y, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet. 2012;49(6):353-361. https://doi.org/10.1136/jmedgenet-2012-100819.

2. Enns GM, Shashi V, Bainbridge M, et al. Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum associated degradation (ERAD) pathway. Genet Med. 2014;16(10):751-758. https://doi.org/10.1038/gim.2014.22.Mutations.
3. Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. *Clin Chem*. 1999;45(9):1517-1522.

4. Kirsch SH, Knapp JP, Geisel J, Herrmann W, Obeid R. Simultaneous quantification of S-adenosyl methionine and S-adenosyl homocysteine in human plasma by stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci*. 2009;877(30):3865-3870. https://doi.org/10.1016/j.jchromb.2009.09.039.

5. Helbig I, Abou Tayoun AN. Understanding genotypes and phenotypes in epileptic encephalopathies. *Mol Syndromol*. 2016;7(4):172-181. https://doi.org/10.1159/000448530.

6. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-291. https://doi.org/10.1038/nature19057.

7. Heeley J, Shinawi M. Multi-systemic involvement in NGLY1-related disorder caused by two novel mutations. *Am J Med Genet Part A*. 2015;167(4):816-820. https://doi.org/10.1002/ajmg.a.36889.

8. Caglayan AO, Comu S, Baranoski JF, et al. NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathy. *Eur J Hum Genet*. 2015;23(8):139-143. https://doi.org/10.1016/j.ejhg.2014.08.008.

9. Lam C, Ferreira C, Krasnewich D, et al. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. *Genet Med*. 2017;19(2):160-168. https://doi.org/10.1038/s41436-016-0072-9.

10. Hirsch C, Blom D, Ploegh HL. A role for N-glycanase in the cytosolic turnover of glycoproteins. *EMBO J*. 2003;22(5):1036-1046. https://doi.org/10.1093/emboj/cdg1107.

11. Tomlin FM, Gerling-Driessen UIM, Liu YC, et al. Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity. *ACS Cent Sci*. 2017;3(11):1143-1155. https://doi.org/10.1021/acscente.7b00224.

12. Huang C, Harada Y, Hosomi A, et al. Endo-β- N-acetylglucosaminidase forms N-GlcNAc protein aggregates during ER-associated degradation in Ngly1-defective cells. *Proc Natl Acad Sci*. 2015;112(5):1398-1403. https://doi.org/10.1073/pnas.1414593112.

13. Fujihira H, Masahara-Negishi Y, Tamura M, et al. Lethality of mice bearing a knockout of the Ngly1-gene is partially rescued by the additional deletion of the Engase gene. *PLoS Genet*. 2017;13(4):1-24. https://doi.org/10.1371/journal.pgen.1006696.

14. Kong J, Peng M, Ostrovsky J, et al. Mitochondrial function requires NGLY1. *Mitochondrion*. 2018;38(May):6-16. https://doi.org/10.1016/j.mito.2017.07.008.

15. Melnyk S, Pogribnà M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular S-Adenosylmethionine and S-Adenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5’-phosphate concentrations. *Clin Chem*. 2000;272:265-272.

16. Anstee QM, Day CP. S-Adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. *J Hepatol*. 2012;57(5):1097-1109. https://doi.org/10.1016/j.jhep.2012.04.041.

17. Mudd SH, Wagner C, Luka Z, et al. Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine. *Mol Genet Metab*. 2011;105(2):228-236. https://doi.org/10.1016/j.ymgme.2011.11.006.

18. Pajares MA. The new levels of redox regulation of S-adenosylmethionine synthesis. https://pdfs.semanticscholar.org/c3ac/945fb7e65b3d12f8805a204ff50839db53f.pdf.

19. Caudill MA, Wang JC, Melnyk S, et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. *J Nutr*. 2001;131(11):2811–2818. doi:0022–3166/01.

---

**How to cite this article:** Chang CA, Wei X-C, Martin SR, Sinasac DS, Al-Hertani W. Transiently elevated plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine: Unreported laboratory findings in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation. *JIMD Reports*. 2019;49:21–29. https://doi.org/10.1002/jmd2.12064